53 related articles for article (PubMed ID: 17575073)
1. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.
Lindström E; von Mentzer B; Påhlman I; Ahlstedt I; Uvebrant A; Kristensson E; Martinsson R; Novén A; de Verdier J; Vauquelin G
J Pharmacol Exp Ther; 2007 Sep; 322(3):1286-93. PubMed ID: 17575073
[TBL] [Abstract][Full Text] [Related]
2. Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A
Vlachodimou A; de Vries H; Pasoli M; Goudswaard M; Kim SA; Kim YC; Scortichini M; Marshall M; Linden J; Heitman LH; Jacobson KA; IJzerman AP
Biochem Pharmacol; 2022 Jun; 200():115027. PubMed ID: 35395239
[TBL] [Abstract][Full Text] [Related]
3. Structures of neurokinin 1 receptor in complex with G
Thom C; Ehrenmann J; Vacca S; Waltenspühl Y; Schöppe J; Medalia O; Plückthun A
Sci Adv; 2021 Dec; 7(50):eabk2872. PubMed ID: 34878828
[TBL] [Abstract][Full Text] [Related]
4. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
Arsova A; Møller TC; Vedel L; Hansen JL; Foster SR; Gregory KJ; Bräuner-Osborne H
Mol Pharmacol; 2020 Jul; 98(1):49-60. PubMed ID: 32358164
[TBL] [Abstract][Full Text] [Related]
5. Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.
van der Velden WJC; Heitman LH; Rosenkilde MM
ACS Pharmacol Transl Sci; 2020 Apr; 3(2):179-189. PubMed ID: 32296761
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B; Trower M; Duggal A; Guglielmini P; Harris P; Jackson D; Lacouture ME; Ratti E; Tonini G; Wood A; Ständer S
BMJ Open; 2020 Feb; 10(2):e030114. PubMed ID: 32034016
[TBL] [Abstract][Full Text] [Related]
7. Probing the CB
Laprairie RB; Vemuri K; Stahl EL; Korde A; Ho JH; Grim TW; Hua T; Wu Y; Stevens RC; Liu ZJ; Makriyannis A; Bohn LM
Mol Pharmacol; 2019 Nov; 96(5):619-628. PubMed ID: 31515283
[TBL] [Abstract][Full Text] [Related]
8. Bioluminescence Resonance Energy Transfer Based G Protein-Activation Assay to Probe Duration of Antagonism at the Histamine H
Mocking TAM; Buzink MCML; Leurs R; Vischer HF
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366084
[TBL] [Abstract][Full Text] [Related]
9. The implications of target saturation for the use of drug-target residence time.
de Witte WEA; Danhof M; van der Graaf PH; de Lange ECM
Nat Rev Drug Discov; 2018 Dec; 18(1):82-84. PubMed ID: 30591716
[No Abstract] [Full Text] [Related]
10. From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.
Nederpelt I; Kuzikov M; de Witte WEA; Schnider P; Tuijt B; Gul S; IJzerman AP; de Lange ECM; Heitman LH
Sci Rep; 2017 Oct; 7(1):14169. PubMed ID: 29075004
[TBL] [Abstract][Full Text] [Related]
11. The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor.
Bosma R; Witt G; Vaas LAI; Josimovic I; Gribbon P; Vischer HF; Gul S; Leurs R
Front Pharmacol; 2017; 8():667. PubMed ID: 29033838
[TBL] [Abstract][Full Text] [Related]
12. Intra-articular injection of a substance P inhibitor affects gene expression in a joint contracture model.
Morrey ME; Sanchez-Sotelo J; Lewallen EA; An KN; Grill DE; Steinmann SP; Yao JJ; Salib CG; Trousdale WH; Reina N; Kremers HM; Lewallen DG; van Wijnen AJ; Abdel MP
J Cell Biochem; 2018 Feb; 119(2):1326-1336. PubMed ID: 28671282
[TBL] [Abstract][Full Text] [Related]
13. A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy.
Bot I; Ortiz Zacarías NV; de Witte WE; de Vries H; van Santbrink PJ; van der Velden D; Kröner MJ; van der Berg DJ; Stamos D; de Lange EC; Kuiper J; IJzerman AP; Heitman LH
Sci Rep; 2017 Mar; 7(1):52. PubMed ID: 28246398
[TBL] [Abstract][Full Text] [Related]
14. Targeting tachykinin receptors in neuroblastoma.
Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
[TBL] [Abstract][Full Text] [Related]
15. Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.
Endo T; Saijo T; Haneda E; Maeda J; Tokunaga M; Zhang MR; Kannami A; Asai H; Suzuki M; Suhara T; Higuchi M
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609595
[TBL] [Abstract][Full Text] [Related]
16. A two-step strategy to enhance activity of low potency peptides.
Doyle JR; Harwood BN; Krishnaji ST; Krishnamurthy VM; Lin WE; Fortin JP; Kumar K; Kopin AS
PLoS One; 2014; 9(11):e110502. PubMed ID: 25391026
[TBL] [Abstract][Full Text] [Related]
17. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.
Steinhoff MS; von Mentzer B; Geppetti P; Pothoulakis C; Bunnett NW
Physiol Rev; 2014 Jan; 94(1):265-301. PubMed ID: 24382888
[TBL] [Abstract][Full Text] [Related]
18. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands.
Mould R; Brown J; Marshall FH; Langmead CJ
Br J Pharmacol; 2014 Jan; 171(2):351-63. PubMed ID: 23692283
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren displays long-lasting interactions with human renin.
Gossas T; Vrang L; Henderson I; Sedig S; Sahlberg C; Lindström E; Danielson UH
Naunyn Schmiedebergs Arch Pharmacol; 2012 Feb; 385(2):219-24. PubMed ID: 22193701
[TBL] [Abstract][Full Text] [Related]
20. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
